Loading...
•
Dec 30, 2023
USANA Q4 2023 Earnings Report
USANA's Q4 2023 earnings exceeded expectations with sales strengthening due to a global incentive offering, particularly effective in the Greater China region, and the commencement of operations in India.
Key Takeaways
USANA Health Sciences reported solid fourth-quarter operating results, exceeding expectations with a 3% decrease in net sales to $221 million but a 32% increase in diluted EPS to $0.87. The company's performance was bolstered by a global incentive offering, especially in Greater China, and the commencement of operations in India.
Q4 net sales reached $221 million, a 3% decrease year-over-year.
Diluted EPS for Q4 was $0.87, a 32% increase year-over-year.
Active Customers in Q4 totaled 483,000, a 1% decrease year-over-year.
The company commenced operations in India, marking its 25th global market.
Revenue by Geographic Location
Forward Guidance
The Company is introducing net sales and earnings per share outlook for fiscal year 2024, as detailed in the table below:
Positive Outlook
- Increased engagement with Associate leaders to further support expansion of their businesses
- Enhanced, market-specific incentive offerings that reward growth
- Expansion of our presence in India
- Product innovation and development
- Pursuit of additional acquisition opportunities
Challenges Ahead
- Challenging economic conditions in many of our markets during 2023
- 2024 will continue to be challenging
- Unfavorable currency exchange rates will have a modest negative impact on net sales in fiscal 2024
- Assumes an operating margin of 8% to 9%, which reflects increased investments in India and our previously acquired businesses
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...